TC BioPharm (Holdings) (TC BioPharm (Holdings)) Cash And Cash Equivalents : $1.25 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Cash And Cash Equivalents?

TC BioPharm (Holdings)'s quarterly cash and cash equivalents increased from Jun. 2023 ($2.42 Mil) to Dec. 2023 ($3.12 Mil) but then stayed the same from Dec. 2023 ($3.12 Mil) to Mar. 2024 ($1.25 Mil).

TC BioPharm (Holdings)'s annual cash and cash equivalents increased from Dec. 2021 ($2.08 Mil) to Dec. 2022 ($5.86 Mil) but then declined from Dec. 2022 ($5.86 Mil) to Dec. 2023 ($3.12 Mil).

TC BioPharm (Holdings) Cash And Cash Equivalents Historical Data

The historical data trend for TC BioPharm (Holdings)'s Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Cash And Cash Equivalents Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

1.25

1.01

2.08

5.86

3.12

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial							5.86	-	2.42	3.12	1.25

TC BioPharm (Holdings) Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

TC BioPharm (Holdings) (NAS:TCBP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

TC BioPharm (Holdings) Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

T0U:Germany

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD